KBKatherine Butcher

Katherine Butcher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katherine Butcher has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developing a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events: A mixed-methods study (Preprint)

    by Erica Lau, Linda Bird, Anthony Lau, Yau-Lam Alex Chau, Katherine Butcher, Susan Buchkowsky, Kira Gossack-Keenan, Cheryl Sadowski, Corinne Hohl

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Adverse drug events (ADE) lead to over two million emergency department visits in Canada annually, resulting in significant patient harm and over $1 billion in healthcare costs. Effective documentation and sharing of ADE information through electronic medical records (EMRs) is essential to inform subsequent care and improve safety when culprit medications can be replaced and re-exposures avoided. Yet current systems often lack standardized comprehensive ADE value sets. Objective: This study aimed to develop a SNOMED CT value set for symptoms and diagnoses to standardize ADE documentation and improve ADE data integration into EMRs. Methods: We used ADE data from ActionADE, a prospective reporting system implemented in nine hospitals in British Columbia. We extracted 5,792 reports that yielded 827 unique ADE symptom and diagnosis terms based on MedDRA preferred terms. Two independent mappers employed both automated and manual mapping approaches to match these terms to SNOMED CT concepts. Two clinical experts conducted validation, followed by a quality assurance review by a separate clinical team. Discrepancies were resolved through consensus discussions. Interrater reliability was assessed using Cohen’s kappa. Results: The automated mapping process identified 63.8% (528/827) semantically equivalent matches from SNOMED CT’s Clinical Finding hierarchy. Two mappers manually reviewed the automatically mapped terms and identified appropriate target concepts for the unmapped terms. After the manual mapping process, 95.3% (788/827) of the source terms were successfully mapped to SNOMED CT concepts, with 4.7% (39/827) remaining unmapped. Interrater reliability between the mappers was strong (κ = 0.87, 95% CI: 0.85-0.89). The validation phase identified and removed one irrelevant term, resulting in 98.9% (778/826) terms mapped, with 1.6% (9/826) unmapped, and a high interrater reliability (κ = 0.88, 95% CI: 0.80-0.95). During quality assurance, six terms were flagged for concerns regarding clinical relevance or safety risks and were resolved through discussions. The final value set comprised 813 SNOMED CT concepts, with 95.0% of terms classified as semantically equivalent. Thirteen additional terms remained unmapped and will be reviewed as new SNOMED CT codes are added. Conclusions: This study developed a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events observed in adults in EMRs. Adopting this value set can improve the consistency, accuracy, and interoperability of ADE documentation in EMRs, helping to reduce repeat ADEs and enhance patient safety. Ongoing refinement and improved clinical usability are essential for its widespread adoption. Future research should assess the impact of integrating this value set into EMRs on ADE reporting, pharmacovigilance, and patient safety outcomes.


  • Open Access

    Characterizing and Comparing Adverse Drug Events Documented in 2 Spontaneous Reporting Systems in the Lower Mainland of British Columbia, Canada: Retrospective Observational Study

    by Erica Y Lau, Amber Cragg, Serena S Small, Katherine Butcher, Corinne M Hohl

    Background: Robust adverse drug event (ADE) reporting systems are crucial to monitor and identify drug safety signals, but the quantity and type of ADEs captured may vary by system characteristics. Objective: We compared ADEs reported in 2 different reporting systems in the same jurisdictions, the Patient Safety and Learning System–Adverse Drug Reaction (PSLS-ADR) and ActionADE, to understand report variation. Methods: This retrospective observational study analyzed reports entered into PSLS-ADR and ActionADE systems between December 1, 2019, and December 31, 2022. We conducted a comprehensive analysis including all events from both reporting systems to examine coverage and usage and understand the types of events captured in both systems. We calculated descriptive statistics for reporting facility type, patient demographics, serious events, and most reported drugs. We conducted a subanalysis focused on adverse drug reactions to enable direct comparisons between systems in terms of the volume and events reported. We stratified results by reporting system. Results: We performed the comprehensive analysis on 3248 ADE reports, of which 12.4% (375/3035) were reported in PSLS-ADR and 87.6% (2660/3035) were reported in ActionADE. Distribution of all events and serious events varied slightly between the 2 systems. Iohexol, gadobutrol, and empagliflozin were the most common culprit drugs (173/375, 46.2%) in PSLS-ADR, while hydrochlorothiazide, apixaban, and ramipril (308/2660, 11.6%) were common in ActionADE. We included 2728 reports in the subanalysis of adverse drug reactions, of which 12.9% (353/2728) were reported in PSLS-ADR and 86.4% (2357/2728) were reported in ActionADE. ActionADE captured 4- to 6-fold more comparable events than PSLS-ADR over this study’s period. Conclusions: User-friendly and robust reporting systems are vital for pharmacovigilance and patient safety. This study highlights substantial differences in ADE data that were generated by different reporting systems. Understanding system factors that lead to varying reporting patterns can enhance ADE monitoring and should be taken into account when evaluating drug safety signals.


  • Open Access

    Characterizing and Comparing Adverse Drug Events Documented in 2 Spontaneous Reporting Systems in the Lower Mainland of British Columbia, Canada: Retrospective Observational Study (Preprint)

    by Erica Y Lau, Amber Cragg, Serena S Small, Katherine Butcher, Corinne M Hohl

    BACKGROUND Robust adverse drug event (ADE) reporting systems are crucial to monitor and identify drug safety signals, but the quantity and type of ADEs captured may vary by system characteristics. OBJECTIVE We compared ADEs reported in 2 different reporting systems in the same jurisdictions, the Patient Safety and Learning System–Adverse Drug Reaction (PSLS-ADR) and ActionADE, to understand report variation. METHODS This retrospective observational study analyzed reports entered into PSLS-ADR and ActionADE systems between December 1, 2019, and December 31, 2022. We conducted a comprehensive analysis including all events from both reporting systems to examine coverage and usage and understand the types of events captured in both systems. We calculated descriptive statistics for reporting facility type, patient demographics, serious events, and most reported drugs. We conducted a subanalysis focused on adverse drug reactions to enable direct comparisons between systems in terms of the volume and events reported. We stratified results by reporting system. RESULTS We performed the comprehensive analysis on 3248 ADE reports, of which 12.4% (375/3035) were reported in PSLS-ADR and 87.6% (2660/3035) were reported in ActionADE. Distribution of all events and serious events varied slightly between the 2 systems. Iohexol, gadobutrol, and empagliflozin were the most common culprit drugs (173/375, 46.2%) in PSLS-ADR, while hydrochlorothiazide, apixaban, and ramipril (308/2660, 11.6%) were common in ActionADE. We included 2728 reports in the subanalysis of adverse drug reactions, of which 12.9% (353/2728) were reported in PSLS-ADR and 86.4% (2357/2728) were reported in ActionADE. ActionADE captured 4- to 6-fold more comparable events than PSLS-ADR over this study’s period. CONCLUSIONS User-friendly and robust reporting systems are vital for pharmacovigilance and patient safety. This study highlights substantial differences in ADE data that were generated by different reporting systems. Understanding system factors that lead to varying reporting patterns can enhance ADE monitoring and should be taken into account when evaluating drug safety signals.